We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Newly Identified Genes May Help to Screen and Treat Individuals with Hearing Loss

By LabMedica International staff writers
Posted on 17 May 2022

A massive genome-wide association study (GWAS) identified 10 novel gene loci associated with hearing loss, which may aid in screening and treating the disorder. More...

Hearing loss is one of the top contributors to years lived with disability and is a risk factor for developing dementia. Hearing loss is a major medical problem worldwide with an estimated 2.4 billion individuals expected to have some form of hearing loss by the year 2050.

Molecular evidence on the cellular origins of hearing loss in humans is growing. In this regard, investigators at King's College London (United Kingdom) and colleagues at Karolinska Institute (Stockholm, Sweden) and Erasmus University (Rotterdam, Netherlands) performed a genome-wide association meta-analysis of clinically diagnosed and self-reported hearing impairment on 723,266 individuals. The study comprised 147,997 affected individuals and 575,269 control subjects including 60,941 affected individuals that were not included in a previously published GWAS meta-analysis.

Results of the meta-analysis revealed 48 genes linked to hearing loss, including 10 novel variants newly linked to hearing.

Contributing author Dr. Frances Williams, professor of genomic epidemiology at King's College London, said, "Our findings identify 10 genes newly linked with hearing loss. This study points to genes we could target for screening purposes, drug development. and even gene therapy in the future. This study provides a solid foundation for ultimately improving therapies against hearing loss."

The study was published in the May 16, 2022, online edition of the American Journal of Human Genetics.

Related Links:
King's College London 
Karolinska Institute 
Erasmus University 

 


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.